| Full text | |
| Author(s): |
Jadel M Kratz
[1]
;
Karolina R Gonçalves
[2]
;
Lavínia MD Romera
[3]
;
Carolina Borsoi Moraes
[4]
;
Paula Bittencourt-Cunha
;
Sergio Schenkman
[6]
;
Eric Chatelain
[7]
;
Sergio Sosa-Estani
Total Authors: 8
|
| Affiliation: | [1] Drugs for Neglected Diseases initiative - Suíça
[2] Universidade de São Paulo. Instituto de Ciências Biomédicas. Departamento de Microbiologia - Brasil
[3] Universidade de São Paulo. Instituto de Ciências Biomédicas. Departamento de Microbiologia - Brasil
[4] Universidade Federal de São Paulo. Departamento de Ciências Farmacêuticas - Brasil
[6] Universidade Federal de São Paulo. Departamento de Microbiologia, Imunologia e Parasitologia - Brasil
[7] Drugs for Neglected Diseases initiative - Suíça
Total Affiliations: 8
|
| Document type: | Journal article |
| Source: | Memórias do Instituto Oswaldo Cruz; v. 117, 2022-05-23. |
| Abstract | |
Chagas disease is a neglected tropical disease caused by the protozoan parasite Trypanosoma cruzi. There is an urgent need for safe, effective, and accessible new treatments since the currently approved drugs have serious limitations. Drug development for Chagas disease has historically been hampered by the complexity of the disease, critical knowledge gaps, and lack of coordinated R&D efforts. This review covers some of the translational challenges associated with the progression of new chemical entities from preclinical to clinical phases of development, and discusses how recent technological advances might allow the research community to answer key questions relevant to the disease and to overcome hurdles in R&D for Chagas disease. (AU) | |
| FAPESP's process: | 19/15909-0 - Studying mechanisms of extracellular vesicle secretion by protozoan parasites |
| Grantee: | Sergio Schenkman |
| Support Opportunities: | Regular Research Grants |